In vitro and in vivo activities of clarithromycin against Mycobacterium avium.
There is no effective therapy to treat Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome. Clarithromycin (A-56268; TE-031) is a new macrolide which is twofold more active than erythromycin against most aerobic bacteria. In addition, higher levels in serum and...
Na minha lista:
| 發表在: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Microbiology (ASM)
1989
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172696/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2530933/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.33.9.1531 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|